Sinovac Biotech LtdNASDAQ:SVA
- LAST PRICE6.4700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 6.4700
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sinovac Biotech Ltd | 639.9M | -1.8x | +15.89% |
P3 Health Partners Inc | 158.0M | -0.7x | --- |
Novavax Inc | 580.8M | -0.7x | --- |
PTC Therapeutics Inc | 1.9B | -3.0x | --- |
Alkermes Plc | 4.2B | 8.1x | --- |
Inotiv Inc | 120.4M | -3.3x | --- |
Company Information
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.
Contact Information
- Headquarters
- No. 39 Shangdi Xi Road, Haidian DistrictBEIJING, BEJ, China 100085
- Phone
- 108-289-0088
- Fax
- 105-693-1800
Executives
- Chairman of the Board, President, Chief Executive Officer, Secretary
- WeiDong Yin
- Chief Financial Officer, Vice President
- Nan Wang
- Chief Operating Officer, Vice President
- Qiang Gao
- Vice President - Quality and Production
- Jing Li
- Chief Business Officer, Investor Relations
- Guang Yang
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $639.9M |
|---|---|
Revenue (TTM) | $420.9M |
Shares Outstanding | 99.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.63 |
Book Value | $89.66 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | 1.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -358.88% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
